Beat AML Master Trial: A Groundbreaking Clinical Trial in Acute Myeloid Leukemia Patients

Meet the Beat AML Team

The Leukemia & Lymphoma Society

- **Amy Burd, Ph.D.**, Vice President, Research Strategy and Special Initiatives, The Leukemia & Lymphoma Society
- **Louis J. DeGennaro, Ph.D.**, President and CEO, The Leukemia & Lymphoma Society

Lead Academic Researchers

- **John Byrd, M.D.**, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; D. Warren Brown Chair of Leukemia Research; professor of medicine and medicinal chemistry and director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center
- **Ross L. Levine, M.D.**, Laurence Joseph Dineen Chair in Leukemia Research, Memorial Sloan Kettering Cancer Center, Director, MSK Center for Hematologic Malignancies
- **Brian Druker, M.D.**, Director of the Knight Cancer Institute at Oregon Health and Science University, Jeld-Wen Chair of Leukemia Research, and Investigator, Howard Hughes Medical Institute

Clinical Trial Site Lead Investigators

- **Martin Tallman, M.D.**, Memorial Sloan Kettering Cancer Center
- **Eytan Stein, M.D.**, Memorial Sloan Kettering Cancer Center
- **William Blum, M.D.**, The Ohio State University Comprehensive Cancer Center
- **Alice Mims, M.D., MSCR**, The Ohio State University Comprehensive Cancer Center
- **Timothy Graubert, M.D.**, Massachusetts General Hospital Cancer Center
- **Amir Fathi, M.D.**, Massachusetts General Hospital Cancer Center
- **Richard Stone, M.D.**, Dana-Farber Cancer Institute
- **Jacqueline Garcia, M.D.**, Dana-Farber Cancer Institute
- **Elie Traer, M.D.**, OHSU Knight Cancer Institute
- **Uma Borate, M.D.**, OHSU Knight Cancer Institute

For more information contact Andrea Greif, LLS senior director of communications, andrea.greif@lls.org or (914) 821-8958.
Genomic Company
- Foundation Medicine

Clinical Research Organization
- INC Research

Pharmaceutical Participants
- To date, multiple pharmaceutical companies have expressed enthusiasm about the trial and are eager to work with LLS on the groundbreaking study.
  
  Current pharmaceutical participants:
  - Alexion
  - Boehringer Ingelheim
  - Celgene
  - Gilead Sciences

Web-Based Digital Protocol Solution
- Protocol First

Clinical Trial Knowledge Platform
- MyClin